


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Previously presented) A compound of formula (I)



A represents thiophene;

R<sup>1</sup> represents a phenyl group; said phenyl being optionally substituted by one or more substituents selected independently from halogen, cyano, nitro, -NR<sup>3</sup>R<sup>4</sup>, -CONR<sup>5</sup>R<sup>6</sup>, -COOR<sup>7</sup>, -NR<sup>8</sup>COR<sup>9</sup>, -SR<sup>10</sup>, -S(O)<sub>m</sub>R<sup>10</sup>, -S(O)<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, -NR<sup>8</sup>SO<sub>2</sub>R<sup>10</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl, trifluoromethyl, -(CH<sub>2</sub>)<sub>n</sub>R<sup>11</sup>, -O(CH<sub>2</sub>)<sub>n</sub>R<sup>11</sup> or -OR<sup>12</sup>;

R<sup>2</sup> represents hydrogen, halogen, cyano, nitro, -NR<sup>13</sup>R<sup>14</sup>, -CONR<sup>15</sup>R<sup>16</sup>, -COOR<sup>17</sup>, -NR<sup>18</sup>COR<sup>19</sup>, -S(O)<sub>m</sub>R<sup>20</sup>, -S(O)<sub>2</sub>NR<sup>15</sup>R<sup>16</sup>, -NR<sup>18</sup>SO<sub>2</sub>R<sup>20</sup>, C<sub>1</sub>-C<sub>2</sub> alkyl, trifluoromethyl, C<sub>2</sub>-C<sub>3</sub> alkenyl, C<sub>2</sub>-C<sub>3</sub> alkynyl, trifluoromethoxy, C<sub>1</sub>-C<sub>2</sub> alkoxy or C<sub>1</sub>-C<sub>2</sub> alkanoyl;

X represents oxygen or sulfur;

each of  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$  and  $R^{12}$  independently represent a hydrogen atom or  $C_1$ - $C_6$  alkyl;

$R^{11}$  represents  $NR^{21}R^{22}$  where  $R^{21}$  and  $R^{22}$  are independently hydrogen or  $C_1$ - $C_6$  alkyl optionally substituted by  $C_1$ - $C_4$  alkoxy; or  $R^{21}$  and  $R^{22}$  together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated ring optionally containing a further O, S or  $NR^{23}$  group where  $R^{23}$  is hydrogen or  $C_1$ - $C_6$  alkyl; or  $R^{11}$  represents  $OR^{24}$  where  $R^{24}$  represents  $C_1$ - $C_6$  alkyl;

each of  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$  and  $R^{20}$  independently represent a hydrogen atom or  $C_1$ - $C_2$  alkyl;

m represents an integer 0, 1 or 2;

n represents an integer 2, 3 or 4;


and optical isomers, racemates, and tautomers thereof and pharmaceutically acceptable salts or solvates thereof:

provided that:

when A represents thiophene, then  $R^1$  is not 4-pyridinyl or 3-pyrazolyl.

2. (Original) A compound of formula (I), according to Claim 1, wherein X represents oxygen.

3. (Previously presented) A compound of formula (I), according to Claim 1, in which the group A is substituted as shown below in formula (Ia), where B and D are selected from  $CR^2$  and S, where  $R^2$  is as defined in Claim 1 and  $R^{25}$  is hydrogen or  $C_1$ - $C_6$  alkyl:



4. (Cancelled)
5. (Cancelled)
6. (Previously presented) A compound according to claim 1 in which  $R^2$  represents H or methyl.
7. (Original) A compound according to Claim 6 in which  $R^2$  represents H.
8. (Original) A compound of formula (I), according to claim 1, selected from:
  - 3-[(aminocarbonyl)amino]-5-phenyl-2-thiophenecarboxamide;
  - 3-[(aminocarbonyl)amino]-5-(3-chlorophenyl)-2-thiophenecarboxamide;
  - 3-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-2-thiophenecarboxamide;
  - 3-[(aminocarbonyl)amino]-5-(4-chlorophenyl)-2-thiophenecarboxamide;
  - 3-[(aminocarbonyl)amino]-5-(4-isobutylphenyl)-2-thiophenecarboxamide;
  - 3-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-2-thiophenecarboxamide;
  - 3-[(aminocarbonyl)amino]-5-(3-hydroxyphenyl)-2-thiophenecarboxamide;
  - 3-[(aminocarbonyl)amino]-5-(2-chlorophenyl)-2-thiophenecarboxamide;
  - 3-[(aminocarbonyl)amino]-5-(2-methoxyphenyl)-2-thiophenecarboxamide;
  - 3-[(aminocarbonyl)amino]-5-{2-[2-(dimethylamino)ethoxy]phenyl}-2-thiophenecarboxamide;
  - 3-[(aminocarbonyl)amino]-5-{4-[2-(dimethylamino)ethoxy]phenyl}-2-thiophenecarboxamide;
  - 3-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)-2-thiophenecarboxamide;
  - 2-[(aminocarbonyl)amino]-5-phenyl-3-thiophenecarboxamide;


3-[(aminocarbonyl)amino]-5-{4-[2-(1-morpholinyl)ethoxy]phenyl}-2-thiophenecarboxamide;  
3-[(aminocarbonyl)amino]-5-{4-[2-(1-pyrrolidinyl)ethoxy]phenyl}-2-thiophenecarboxamide;  
3-[(aminocarbonyl)amino]-5-{4-[2-(1-piperidinyl)ethoxy]phenyl}-2-thiophenecarboxamide;  
3-[(aminocarbonyl)amino]-5-{4-[3-(dimethylamino)propoxy]phenyl}-2-thiophenecarboxamide;  
3-[(aminocarbonyl)amino]-5-{3-[2-(dimethylamino)ethoxy]phenyl}-2-thiophenecarboxamide;  
3-[(aminocarbonyl)amino]-5-{3-[2-(1-morpholinyl)ethoxy]phenyl}-2-thiophenecarboxamide;  
3-[(aminocarbonyl)amino]-5-{3-[2-(1-pyrrolidinyl)ethoxy]phenyl}-2-thiophenecarboxamide;  
3-[(aminocarbonyl)amino]-5-{3-[2-(1-piperidinyl)ethoxy]phenyl}-2-thiophenecarboxamide;  
3-[(aminocarbonyl)amino]-5-{3-[3-(dimethylamino)propoxy]phenyl}-2-thiophenecarboxamide;  
3-[(aminocarbonyl)amino]-5-{2-[2-(1-morpholinyl)ethoxy]phenyl}-2-thiophenecarboxamide;  
3-[(aminocarbonyl)amino]-5-{2-[2-(1-pyrrolidinyl)ethoxy]phenyl}-2-thiophenecarboxamide;  
3-[(aminocarbonyl)amino]-5-{2-[2-(1-piperidinyl)ethoxy]phenyl}-2-thiophenecarboxamide;  
3-[(aminocarbonyl)amino]-5-{2-[3-(dimethylamino)propoxy]phenyl}-2-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-4-methyl-5-(4-chlorophenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-4-methyl-5-(4-methylphenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-4-ethyl-5-phenyl-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-4-methyl-5-(4-methoxyphenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-4-methyl-5-(4-fluorophenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-4-methyl-5-(3-fluorophenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-4-methyl-5-(3-methoxyphenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-4-methyl-5-(3-chloro-4-methoxyphenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-4-methyl-5-(2-chlorophenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-4-methyl-5-(3-trifluoromethylphenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-4-methyl-5-(3-methyl-4-methoxyphenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-4-methyl-5-(3,5-dimethoxyphenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-4-methyl-5-(2,3-dimethoxyphenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-4-methyl-5-(4-isopropylphenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-4-methyl-5-(3,4,5-trimethoxyphenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-4-methyl-5-(3,4-dichlorophenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-4-methyl-5-(4-cyanophenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-4-methyl-5-(4-hydroxyphenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-4-methyl-5-(4-[2-(1-piperidinyl)ethoxy]phenyl)-3-  
thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-4-methyl-5-(4-[2-(diethylamino)ethoxy]phenyl)-3-  
thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-4-trifluoromethyl-5-phenyl-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-4-methyl-5-phenyl-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-5-(4-cyanophenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-5-(4-trifluoromethylphenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-5-(2,4-difluorophenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-5-(4-chlorophenyl)-3-thiophenecarboxamide;

2-[(aminocarbonyl)amino]-5-(4-methanesulphonylphenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-5-(4-[2-(1-piperidinyl)ethoxy]phenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-5-(4-[2-(1-(2,2,6,6-tetramethyl)piperidinyl)ethoxy]phenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-5-(4-(thiazol-4-yl-methoxy)phenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-5-(4-[2-(dimethylamino)ethoxy]phenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-5-(4-[2-(diethylamino)ethoxy]phenyl)-3-thiophenecarboxamide;  
2-[(aminocarbonyl)amino]-5-(4-[2-(1-morpholinyl)ethoxy]phenyl)-3-thiophenecarboxamide;  
2-[(aminothiocabonyl)amino]-5-phenyl-3-thiophenecarboxamide;  
and pharmaceutically acceptable salts and solvates thereof.

9. (Previously presented) A process for the preparation of a first compound of formula (I), according to claim 1, which comprises:


(a) reaction of a compound of formula (II):



wherein A, R<sup>1</sup> and R<sup>2</sup> are as defined in Claim 1, with an isocyanate (X = O) or an isothiocyanate (X = S), to produce the first compound of formula (I); or

(b) reaction of compound of formula (III) with a compound of formula (IV)

R<sup>1</sup>-Metal




(III)

(IV)

wherein A, X, R<sup>1</sup> and R<sup>2</sup> are as defined in Claim 1, and LG represents a leaving group, to produce the first compound of formula (I); or

(c) reaction of compound of formula (V) with a compound of formula (VI)

R<sup>1</sup>-LG



(V)

(VI)

wherein A, X, R<sup>1</sup> and R<sup>2</sup> are as defined in Claim 1, and LG represents a leaving group, to produce the first compound of formula (I).

10. (Previously presented) A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

11. (Previously presented) A process for the preparation of a pharmaceutical composition which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or

solvate thereof, as claimed in claim 1 with a pharmaceutically acceptable adjuvant, diluent or carrier.

12-19. (Cancelled)

20. (Previously presented) A method of treating an IKK2 mediated disease which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1.

21. (Previously presented) A method of treating an inflammatory disease, or a disease with an inflammatory component, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1.

22. (Original) A method according to claim 21, wherein the disease is asthma.

23. (Original) A method according to claim 21, wherein the disease is rheumatoid arthritis.

24. (Original) A method according to claim 21, wherein the disease is multiple sclerosis.

25. (Original) A method according to claim 21, wherein the disease is chronic obstructive pulmonary disease.

26. (Previously presented) A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 8, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.



27. (Previously presented) A process of claim 9, further comprising converting the first compound of formula (I), or a salt thereof, into a pharmaceutically acceptable salt thereof; or converting the first compound of formula (I) into a second compound of formula (I).
28. (Previously presented) A process of claim 9, further comprising converting the first compound of formula (I) into an optical isomer thereof.
29. (Previously presented) A method of claim 21, wherein the disease is rhinitis.